Literature DB >> 1760817

Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K.

E Yefenof1, E Einat, E Klein.   

Abstract

C57BL mice inoculated with radiation leukemia virus (RadLV) develop preleukemic cells long before the onset of leukemia. These cells are potentially immunogenic but fail to elicit an immune response in the host because of the appearance of virus-specific suppressor T cells. We have studied the effect of polysaccharide K (PSK) on the generation of RadLV-specific cell-mediated immune responses in vitro. Long-term exposure to PSK in culture potentiated the ability of immunized T cells to respond to a RadLV-induced lymphoma. It also abrogated the suppressive activity of suppressor T cells and simultaneously boosted the ability of reactive T cells to respond. The dual immunostimulating activity of PSK resulted in the generation of T cytotoxic lymphocytes that could lyse lymphoma cells in vitro. The results suggest that PSK could be used as a prophylactic immune response modifier in preleukemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760817     DOI: 10.1007/bf01741348

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

Review 1.  Induction of leukemia in mice by irradiation and radiation leukemia virus variants.

Authors:  N Haran-Ghera; A Peled
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

2.  A highly leukemogenic radiation leukemia virus isolate is a thymotropic, immunosuppressive retrovirus with a unique RNA structure.

Authors:  Y Ben David; M Kotler; E Yefenof
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

3.  Spontaneous and induced preleukemia cells in C57BL/6 mice:brief communication.

Authors:  N Haran-Ghera
Journal:  J Natl Cancer Inst       Date:  1978-03       Impact factor: 13.506

4.  Preleukemic cells induced by RadLV are of an oligoclonal nature.

Authors:  E Yefenof; Y Ben-David; M Kotler
Journal:  Leukemia       Date:  1988-12       Impact factor: 11.528

5.  High- and low-leukemogenic variants of the radiation leukemia virus (RadLV): immunogenic, suppressive and genetic properties in relation to leukemogenic activity.

Authors:  E Yefenof; Y Ben David; M Kotler
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

Review 6.  Krestin (PSK).

Authors:  S Tsukagoshi; Y Hashimoto; G Fujii; H Kobayashi; K Nomoto; K Orita
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

7.  Effects of PSK on specific tumor immunity to syngeneic tumor cells.

Authors:  S Tsuru; K Nomoto
Journal:  J Clin Lab Immunol       Date:  1983-04

8.  Protective effect of biological response modifiers on murine cytomegalovirus infection.

Authors:  K Ebihara; Y Minamishima
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Immunity and suppression in radiation- and radiation leukemia virus (RadLV)-induced leukemogenesis.

Authors:  E Yefenof; Y Ben-David
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

10.  Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats.

Authors:  Y Mizushima; N Yuhki; M Hosokawa; H Kobayashi
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

View more
  2 in total

1.  The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells.

Authors:  F Vánky; P Wang; E Klein
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K.

Authors:  E Yefenof; I Gafanovitch; E Oron; M Bar; E Klein
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.